Publications
Partners
Shutterstock
Basel - Novartis and Malaria No More have announced the debut of the Power of One (http://www.Po1.org) campaign, encouraging people worldwide to help end child deaths from malaria.
Novartis will support the campaign financially and donate up to three million Coartem® Dispersible treatments to match antimalarials funded by the public.
The company’s commitment aligns with its long history in the fight against malaria and the Novartis malaria initiative is one of the largest access-to-medicine programmes in the healthcare industry.
Malaria is a preventable and treatable disease, but it still kills a child every minute.
It is estimated over 300 million additional treatments will be needed to treat malaria patients across Africa between now and the end of 2015.
The Power of One campaign aims to address the treatment gap through direct donations and existing government commitments.
Every dollar donated to the campaign will buy and deliver a treatment to a child diagnosed with malaria.
Networks
The CEO of Novartis, Joseph Jimenez, said: “I'm proud of the significant and longstanding commitment Novartis has to the fight against malaria.
"For all our progress though, there’s still more work to do and we need more help to close the treatment gap.
"The Power of One offers everyone a chance to engage and make a difference for children suffering from malaria.”
Harnessing social, mobile, and e-commerce technologies, Power of One enables the public to purchase a treatment and track its journey.
Donors will be able to see the effect of their donation on the ground, share information with their networks and recruit other donors.
“It’s unacceptable that a child dies every minute for lack of a dollar’s worth of treatment,” said Martin Edlund, CEO, Malaria No More.
“We’re urging the world to join the Power of One campaign and to donate and engage their friends in this fight.”
Children
Novartis is the exclusive treatment sponsor of the Power of One campaign, joining some of the world’s most innovative companies.
Additional sponsors include Alere, which will provide malaria rapid diagnostic tests, as well as 21st Century Fox, AHAlife.com, Causes.com, Time Warner, Twitter, Venmo and others.
Zambia will be the first country to receive deliveries of treatments and tests as a result of the Power of One campaign.
Since 2009, Novartis has delivered 200 million treatments of its paediatric antimalarial Coartem® Dispersible without profit to more than 50 malaria-endemic countries.
Never before have so many paediatric treatments been distributed in such a short timeframe for children suffering from malaria.
The 200 millionth treatment was delivered to Zambia, which also received the first consignment of Novartis treatments for the Power of One campaign, raised during World Malaria Day on 25 April this year.
For more information: http://www.malaria.novartis.com
Photo: Mosquito from Shutterstock
For Novartis multimedia content, please visit http://www.thenewsmarket.com/Novartis
Novartis will support the campaign financially and donate up to three million Coartem® Dispersible treatments to match antimalarials funded by the public.
The company’s commitment aligns with its long history in the fight against malaria and the Novartis malaria initiative is one of the largest access-to-medicine programmes in the healthcare industry.
Malaria is a preventable and treatable disease, but it still kills a child every minute.
It is estimated over 300 million additional treatments will be needed to treat malaria patients across Africa between now and the end of 2015.
The Power of One campaign aims to address the treatment gap through direct donations and existing government commitments.
Every dollar donated to the campaign will buy and deliver a treatment to a child diagnosed with malaria.
Networks
The CEO of Novartis, Joseph Jimenez, said: “I'm proud of the significant and longstanding commitment Novartis has to the fight against malaria.
"For all our progress though, there’s still more work to do and we need more help to close the treatment gap.
"The Power of One offers everyone a chance to engage and make a difference for children suffering from malaria.”
Harnessing social, mobile, and e-commerce technologies, Power of One enables the public to purchase a treatment and track its journey.
Donors will be able to see the effect of their donation on the ground, share information with their networks and recruit other donors.
“It’s unacceptable that a child dies every minute for lack of a dollar’s worth of treatment,” said Martin Edlund, CEO, Malaria No More.
“We’re urging the world to join the Power of One campaign and to donate and engage their friends in this fight.”
Children
Novartis is the exclusive treatment sponsor of the Power of One campaign, joining some of the world’s most innovative companies.
Additional sponsors include Alere, which will provide malaria rapid diagnostic tests, as well as 21st Century Fox, AHAlife.com, Causes.com, Time Warner, Twitter, Venmo and others.
Zambia will be the first country to receive deliveries of treatments and tests as a result of the Power of One campaign.
Since 2009, Novartis has delivered 200 million treatments of its paediatric antimalarial Coartem® Dispersible without profit to more than 50 malaria-endemic countries.
Never before have so many paediatric treatments been distributed in such a short timeframe for children suffering from malaria.
The 200 millionth treatment was delivered to Zambia, which also received the first consignment of Novartis treatments for the Power of One campaign, raised during World Malaria Day on 25 April this year.
For more information: http://www.malaria.novartis.com
Photo: Mosquito from Shutterstock
For Novartis multimedia content, please visit http://www.thenewsmarket.com/Novartis
